Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313530 | 0.92 | CNR1 (0.37) | CNR1SLC34A1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10275758 | 0.88 | PDE2A (0.40) | PDE2ASLC11A2CCNA2CDK2TDP2 | |
| SCHEMBL10276513 | 0.82 | CNR1 (0.38) | CNR1SLC34A1PDE2ASLC11A2CCNA2 | |
| SCHEMBL10275434 | 0.80 | KIF11 (0.46) | CNR1SLC34A1PDE2ACYP3A4 | |
| SCHEMBL10276114 | 0.78 | PGR (0.39) | PDE2ACYP2C9CYP3A4CYP2C19 | |
| SCHEMBL10275596 | 0.76 | PGR (0.38) | PDE2ACYP2C9CYP3A4CYP2C19PTGS2 | |
| SCHEMBL10313529 | 0.74 | CNR1 (0.37) | CNR1SLC34A1CYP2C9CYP3A4PTGS2 | |
| SCHEMBL10313488 | 0.74 | ALDH1A1 (0.34) | CYP2C9CYP3A4CYP2C19PTGS2 | |
| SCHEMBL10276117 | 0.71 | CNR1 (0.41) | CNR1SLC34A1PDE2ASLC11A2CYP2C9 | |
| SCHEMBL12826199 | 0.70 | CCNA2 (0.37) | CNR1PDE2ASLC11A2CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | CNR1 877/4885SLC34A1 474/4885PDE2A 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.